News
People lost more weight on Zepbound
Digest more
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
Zacks Investment Research on MSN1d
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...
Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...
Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...
Eli Lilly launched a couple of new successful drugs, Mounjaro and Zepbound, that have boosted ... In 2021, Pfizer's COVID-19 vaccine success had many wondering how to invest in Pfizer.
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback